thinkpool

['폴리티코(POLITICO)'가 6월 19일 바이오시밀러 포럼을 개최합니다]

폴리티코는 미국의 저명한 정치전문 일간신문입니다. 정치, 사회적으로 큰 영향력을 행사하는 언론신문으로

이번 포럼서 '하늘 높은 줄 모르는 미국의 약가 정책을 비판하고, 유럽대비 10년이상 뒤진 원인 등을 분석해서 바이오시밀러 도입을 앞당기라는 정치적인 압박을 가할 것으로 생각됩니다.

미 정치인들이 영향력이 큰 폴리티코 눈치를 볼 수 밖에 없기에, 폴리티코의 바이오시밀러 포럼 개최의 중요한 의미가 있을 것으로 봅니다

https://www.politico.com/live-events/2019/06/19/americas-sky-high-drug-prices-the-role-of-biosimilars-1351903

[America’s Sky-High Drug Prices & the Role of Biosimilars]

Americans have grown accustomed to using generic drugs, which are cheaper copycat versions of brand-name medicines. A biosimilar drug is similar, but not identical to an already-approved biologic drug, which is often derived from living organisms. There were high hopes these products could increase competition with branded biologics to lower health care spending and patients’ out-of-pocket costs. But the U.S. biosimilars market has lagged behind Europe’s for more than a decade due to a variety of issues ？ lack of payer activity, drug substitution policies, financial and regulatory concerns. Among these, it’s not clear how much money can be saved using biosimilars over biologics to fight certain diseases.

Join POLITICO on Wednesday, June 19, for a deep-dive conversation to discuss the obstacles to getting biosimilars into the U.S. market, how effective biosimilars will be in increasing health care savings and where biologics and biosimilars fit into the broader strategies for Medicare or other health care purchasers looking to cut costs.